{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:53:46Z","timestamp":1759366426822,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.revmed.2008.12.024","type":"journal-article","created":{"date-parts":[[2009,3,24]],"date-time":"2009-03-24T04:18:07Z","timestamp":1237868287000},"page":"477-485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Rhabdomyolyse et \u00e9l\u00e9vation des enzymes musculaires sous olanzapine"],"prefix":"10.1016","volume":"30","author":[{"given":"S.","family":"Ribeyron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Guy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Cath\u00e9bras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2008.12.024_bib1","series-title":"Manuel de psychiatrie","first-page":"524","article-title":"Les antipsychotiques","author":"Llorca","year":"2007"},{"key":"10.1016\/j.revmed.2008.12.024_bib2","first-page":"5","article-title":"Olanzapine dans le traitement de la schizophr\u00e9nie. \u00c9valuation clinique","volume":"vol. 23","author":"Fratta","year":"2002"},{"key":"10.1016\/j.revmed.2008.12.024_bib3","first-page":"2106","article-title":"L\u2019olanzapine (Zyprexa\u00ae)","volume":"29","author":"Sahebjam","year":"2000","journal-title":"Presse Med"},{"issue":"suppl.4","key":"10.1016\/j.revmed.2008.12.024_bib4","first-page":"S518","article-title":"Camptocormie, rhabdomyolyse aigu\u00eb, et olanzapine\u00a0: \u00e0 propos de 2\u00a0cas","volume":"28","author":"Koenig","year":"2007","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2008.12.024_bib5","unstructured":"Les rhabdomyolyses. Entre simples douleurs musculaires et insuffisance r\u00e9nale aigu\u00eb. Prescrire 2003;23:537\u20139."},{"key":"10.1016\/j.revmed.2008.12.024_bib6","unstructured":"American Psychiatric Association. DSM-IV-TR. Manuel diagnostique et statistique des troubles mentaux, 4e\u00a0\u00e9dition, texte r\u00e9vis\u00e9 (Washington DC; 2000). Paris: Masson; 2003."},{"key":"10.1016\/j.revmed.2008.12.024_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/hup.483","article-title":"Olanzapine induced neuroleptic malignant syndrome \u2013 a case review","volume":"18","author":"Kogoj","year":"2003","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.revmed.2008.12.024_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1517\/14740338.2.1.21","article-title":"Neuroleptic malignant syndrome induced by atypical antipsychotics","volume":"2","author":"Farver","year":"2003","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.revmed.2008.12.024_bib9","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.4088\/JCP.v69n0716","article-title":"Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases","volume":"69","author":"Croarkin","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.revmed.2008.12.024_bib10","first-page":"111","article-title":"Imputabilit\u00e9 des effets inattendus ou toxiques des m\u00e9dicaments. Actualisation de la m\u00e9thode utilis\u00e9e en France","volume":"40","author":"Begaud","year":"1985","journal-title":"Therapie"},{"key":"10.1016\/j.revmed.2008.12.024_bib11","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1345\/aph.18282","article-title":"Marked elevation of serum creatine kinase associated with olanzapine therapy","volume":"33","author":"Marcus","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.revmed.2008.12.024_bib12","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1345\/aph.10370","article-title":"Olanzapine-induced rhabdomyolysis","volume":"35","author":"Rosebraught","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.revmed.2008.12.024_bib13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4088\/JCP.v64n0420f","article-title":"Olanzapine elevation of serum creatine kinase","volume":"64","author":"Marti-Bonmati","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.revmed.2008.12.024_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1055\/s-2005-837770","article-title":"Olanzapine-induced acute rhabdomyolysis: a case report","volume":"38","author":"Baumgart","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.revmed.2008.12.024_bib15","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s00210-005-0004-7","article-title":"Serum creatine kinase as a possible complication of therapy with olanzapine","volume":"372","author":"Perlov","year":"2005","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.revmed.2008.12.024_bib16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s002130000539","article-title":"Antipsychotic drugs, serum creatine kinase (CPK) and possible mechanisms","volume":"152","author":"Devarajan","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.revmed.2008.12.024_bib17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s002130000464","article-title":"Massive increase in serum creatine kinase during olanzapine and quietapine treatment, not during treatment with clozapine","volume":"150","author":"Boot","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.revmed.2008.12.024_bib18","first-page":"51","article-title":"Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects","volume":"42","author":"Conley","year":"2005","journal-title":"Isr J Psychiatry Relat Sci"},{"key":"10.1016\/j.revmed.2008.12.024_bib19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/0893-133X(95)00276-J","article-title":"Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment","volume":"15","author":"Meltzer","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.revmed.2008.12.024_bib20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1177\/0960327106073832","article-title":"Olanzapine overdose is associated with acute muscle toxicity","volume":"25","author":"Waring","year":"2006","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.revmed.2008.12.024_bib21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s002130000465","article-title":"Massive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message?","volume":"150","author":"Meltzer","year":"2000","journal-title":"Psychopharmacology"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886630900071X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886630900071X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:23:55Z","timestamp":1759335835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S024886630900071X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S024886630900071X"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2008.12.024","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2009,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rhabdomyolyse et \u00e9l\u00e9vation des enzymes musculaires sous olanzapine","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2008.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Soci\u00e9t\u00e9 nationale fran\u00e7aise de m\u00e9decine interne (SNFMI). Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}